App Store

Google Play

DK - Details page - Device banner - 894x1036

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

Lyt når som helst, hvor som helst 

Bloomberg

Reality TV stars are freezing their eggs on camera. Lawmakers in DC are debating federal protection for IVF. Hundreds of millions of dollars are being invested in slick startups that market fertility treatments for all. But this rapid growth has revealed cracks in the system. Misconception, a new series from Bloomberg’s Prognosis, follows reporter Kristen V. Brown on her own intimate journey as she uncovers the business of fertility. Along the way, she finds a fractured industry — a profit-driven field of medicine that thrives on dueling messages of hope and fear as people gamble everything for a chance at a baby.

Prognosis: Losing it

When dozens of young women discover manipulated photos of themselves have been posted on a porn site, they fight back – joining up with a global band of investigators and hackers to battle the AI-fueled rise of deepfakes. Listen to episodes starting March 21.

See omnystudio.com/listener for privacy information.

Introducing: Levittown

Where does a medical cure come from? 100 years ago, it wasn't uncommon for scientists to test medicines by taking a dose themselves. As medical technologies get cheaper and more accessible, patients and DIY tinkerers are trying something similar—and mainstream medicine is racing to catch up. Prognosis explores the leading edge of medical advances, and asks who gets—or should get—access to them. We look at how innovation happens, when it fails, and what it means to the people with a disease trying to feel better, live longer, or avoid death.

See omnystudio.com/listener for privacy information.

Prognosis, a New Show From Bloomberg

More than a million Americans suffer from Type 1 diabetes. The disease occurs when the pancreas mysteriously stops producing insulin, the hormone that converts food into energy. Modern medicine has been able to recreate insulin, but not the finely calibrated delivery mechanism of the pancreas. Now a group of like-minded do-it-yourselfers have gotten together on the internet and—working outside the purview of organized medicine—have figured out how to link a pump, glucose monitor and smartphone to simulate a functioning pancreas. The results have been spectacularly successful.

See omnystudio.com/listener for privacy information.

How To Build Your Own Artificial Pancreas

If you had told people from the 1970s that few decades later the globe would be connected with powerful computers held in the palm of your hand, they could be forgiven for thinking you were seriously deluded. Now, a growing number of scientists are convinced we're on a similar threshold with genetic engineering. Today we'll take you on a tour of a biohacker's DNA experiment to change how frogs—and possibly people—grow muscles. It's an experiment which he insists anyone can try at home. He'll even sell you a kit—frogs included—to do it.

See omnystudio.com/listener for privacy information.

Biohacking a Ripped Frog

In episode three of Prognosis, Kristen V. Brown and Sarah McBride take a trip to Burning Man. They're there to follow Rick Doblin, who has become something of a folk hero for those who believe MDMA—Ecstasy—could be a viable clinical treatment for things like PTSD. But to help push an illegal drug into the mainstream, it takes lots of cash. And to find money for an unconventional treatment, what better place than Burning Man?

See omnystudio.com/listener for privacy information.

Searching For a Cure to PTSD at Burning Man

Eighteen years ago, scientists decoded the human genome. But what was supposed to create an era of new cures didn't work out that way, at least not at first. In episode four of Prognosis, some of the most famous names in genetics explain why it took so long to go from mapping life's code to actually helping people, laying the foundations for technologies on the scientific and ethical cutting edge, like modifying people's genes. 

See omnystudio.com/listener for privacy information.

Decoding the Genome Was Just the Beginning

Researchers and pharmaceutical companies have poured time and money into developing an effective drug to combat obesity. But time and again, the drugs have failed to deliver. In episode five of Prognosis, Bloomberg's James Paton talks to scientists on the cutting edge of weight-loss research, and the companies that may finally be close to finding a medical solution to the obesity crisis.

See omnystudio.com/listener for privacy information.

The Quest for a Weight-Loss Drug That Actually Works

When you pick up your prescription at the pharmacy, do you ever wonder how that pill made it your way? Who discovered it? Who believed in it when no one else did? Who invested the money to bring it to market? This week on Prognosis, Bloomberg's Rebecca Spalding tells the surprising journey of one life-saving drug, from discovery to market. It's a story about a Nobel Prize winner, cutting edge genetic research, billions of pharmaceutical dollars, and of all things, a worm. What does it tell us about health care in America?

See omnystudio.com/listener for privacy information.

One Drug's Journey

Should a patient dying of a disease with no proven cure have the right to try whatever experimental drug they want? A controversial new law signed by President Trump this year says that they should, bypassing the FDA. In episode seven, Bloomberg's Michelle Fay Cortez explores what the new Right To Try law means for desperate patients who want access to experimental treatments. It isn't as simple as it sounds.

See omnystudio.com/listener for privacy information.

Right to Try, Right to Fail

Some patients can't wait for pharmaceutical companies to develop drugs. They're pushing the drug industry to make the cures they and their loved ones need. But what's good for patients is also good for pharma's profits, creating a web of murky incentives that makes the issue of high drug costs all the more difficult to parse. In episode 8, Bloomberg's Rebecca Spalding talks to these professional patients about their relationships to the big companies whose therapies they need.

See omnystudio.com/listener for privacy information.

How to Buy a Cure

When Covid-19 hit, Gilead Sciences Inc. had enough of its experimental drug remdesivir ready to test and start manufacturing it at a larger scale. That's because it had started stockpiling not just the drug, but its ingredients, at the first hint there may be a new coronavirus. Robert Langreth reports on why the company was able to act early to prepare for a pandemic when so many businesses and institutions did not.

See omnystudio.com/listener for privacy information.

This Drug Maker Saw the Pandemic Coming

Lyt når som helst, hvor som helst

Other podcasts you might like ...